A single-center, randomized, double-blind, placebo-controlled clinical trial of combined rosiglitazone/metformin (Avandamet) vs. placebo on serological outcomes in non-diabetic patients with stable coronary syndromes.

Trial Profile

A single-center, randomized, double-blind, placebo-controlled clinical trial of combined rosiglitazone/metformin (Avandamet) vs. placebo on serological outcomes in non-diabetic patients with stable coronary syndromes.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2011

At a glance

  • Drugs Rosiglitazone/metformin (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROMANCE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Planned end date changed from 1 Jun 2009 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top